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1 
INTRODUCTION 
Guillain-Barré Syndrome is the commonest cause of acquired demyelinating 
disorders affecting the peripheral nervous system in any part of the world. It is a 
spectrum of illness of diverse etiology with a common pathological process. It is a 
non-seasonal illness affecting persons of all age groups.  
The severity of Guillain-Barré Syndrome varies from mild weakness to total 
paralysis and respiratory failure, sometimes leading to death. 
Proper understanding of pathology, clinical presentation, appropriate 
investigations and interventions when needed may save these patients from mortality 
and severe morbidity. 
Thanjavur Medical College and Hospital predominantly covers rural population 
of Tamilnadu.  It offers medical management to all economic status of people, all 
religions and all age groups.  It is more ideal to conduct a study in this institution. 
The diagnosis of Guillain-Barré Syndrome is made predominantly by clinical 
methods and aided by investigations like cerebrospinal fluid analysis and 
electrodiagnostic studies. 
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AIMS OF THE STUDY 
1. To evaluate the types and antecedent events of Guillain-Barré Syndrome  
2. To find out the incidence of Guillain-Barré Syndrome 
3. To analyze the temporal profile of illness and its clinical features 
4. To assess the severity of illness with reference to cerebrospinal fluid analysis 
and electrodiagnostic studies  
5. To assess the prognostic outcome with electrodiagnostic studies 
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HISTORICAL REVIEW 
History of Guillain-Barré Syndrome divides into 
1. 1843 – 1916:  DESCRIPTION OF THE SYNDROME 32 
1843 – Robert Graves recognized that peripheral nerve disease could lead                       
               to paralysis.  
1859 – Jean Baptiste Octave Landry found the paralytic disease without central            
lesions might be due to peripheral nerve involvement1, 28.                   
1864 - Dumenil in Rouen reported first pathologic demonstration of nerve   
disease. 
1880 – First autopsy description of lymphocytic inflammation by Leyden. 
Early 1890s – Osler used the term acute febrile polyneuritis1. 
 
2. 1916 -1969: SETTING BOUNDARIES32  
1916 - Georges Guillain, Jean-Alexandre Barré and Andre Strohl described two 
paralyzed French soldiers1,48.  Their novel contribution was the 
demonstration of elevated spinal fluid protein without cells28.  
1960s - Advent of Electrodiagnosis – Landmark in diagnosis of Guillain-Barré 
Syndrome. Hay maker and Kernohan-definite identification of 
demyelination1.   
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3. 1969 – PRESENT MECHANISMS AND TREATMENTS32 
1969 -  Asbury, Amason, Adams demonstrated analogy between 
Guillain-Barré Syndrome and Experimental Allergic Neuritis 
(EAN) in animals1.  
 Mid 1980s – First effective immunotherapy – the new technique 
of plasmapheresis.   Second – infusion of intravenous 
immunoglobulin.              
Yuki – First demonstrated molecular mimicry in post-
Campylobacter Guillain-Barré Syndrome. 
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REVIEW OF LITERATURE 
 
DEFINITION 
  Guillain-Barré Syndrome can be defined as an acquired, immunologically 
mediated or autoimmune, acute, inflammatory, demyelinating, 
polyradiculoneuropathy (AIDP) 28.  The most frequent cause of acute flaccid paralysis 
worldwide, 4, 30 are also among the most dramatic neurologic emergencies.    
 
SYNONYMS5 
  Acute post - infective polyradiculoneuropathy 
  Acute infectious polyneuritis 
  Landry - Guillain-Barré - Strohl syndrome 
     Post - infective polyneuritis 
 
INCIDENCE 
• Reported incidence rate has varied from 0.4 to 1.7 cases per 100,000 
persons per year (Ropper et al 1991)1,12,42,44 
• Non – seasonal, non-epidemic illness, affects persons of all ages1,25 
• Reports from India and China indicate peak incidence between July and 
October28 
• Females are slightly more susceptible1 
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CLASSIFICATION OF THE GUILLAIN-BARRÉ SYNDROME SUBTYPES1, 35, 44, 48 
1. Acute inflammatory demyelinating polyradiculoneuropathy 
2. Acute motor axonal neuropathy 
3. Acute motor sensory axonal neuropathy 
4. Miller – Fisher Syndrome 
5. Acute pandysautonomia 
6. Sensory Guillain-Barré Syndrome 
7. Cervico-brachial-pharyngeal, often with ptosis 
8. Bilateral facial or abducens weakness with distal paresthesias 
 
DIAGNOSTIC CRITERIA OF AIDP 
(ASBURY AND CORNBLATH 1990)4, 12,23,44,48 
 
FEATURES REQUIRED FOR DIAGNOSIS 
• Progressive weakness in both arms and both legs  
• Areflexia 
FEATURES STRONGLY SUPPORTING THE DIAGNOSIS 
• Progression of symptoms over four days to four weeks 
• Relative symmetry of symptoms 
• Mild sensory symptoms or signs 
• Cranial nerve involvement especially bilateral weakness of facial  
muscles 
• Recovery beginning 2 - 4 wks after progression ceases  
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• Autonomic dysfunction 
• Absence of fever at the onset 
• Elevated concentration of proteins in the cerebrospinal fluid with less 
than 10  mononuclear cells per cubic mm 
• Typical electro diagnostic features 
FEATURES MAKING THE DIAGNOSIS DOUBTFUL  
• Sensory level 
• Marked persistent asymmetry of symptoms and signs 
• Severe or persistent bladder or bowel dysfunction   
• More than 50 mononuclear cells per cubic mm in cerebrospinal fluid 
• Presence of polymorphonuclear leucocytes in cerebrospinal fluid  
FEATURES EXCLUDING THE DIAGNOSIS 
• Diagnosis of Botulism, Myasthenia, Poliomyelitis or Toxic neuropathies 
• Abnormal porphyrin metabolism 
• Recent diphtheria 
• Purely sensory syndrome without weakness 
• Features clinically consistent with lead neuropathy 
• History of hexacarbon (volatile solvent) abuse46 
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CLINICAL MANIFESTATIONS  
Guillain-Barré Syndrome is typically a monophasic illness50.  Approximately, 
two thirds of patients report a preceding event, 1- 4 weeks before the onset of 
neurological symptoms (Govoni and Granieri 2001)8. 
ANTECEDENT EVENTS1, 5, 12,19,28,48 
1. Respiratory illness 58% 
2. Gastrointestinal illness 22% 
3. Respiratory and gastrointestinal illness - 10% 
4. Surgery – 5% (Winer et al) 
5. Vaccination - 3% 
• 1976 A / New Jersey influenza vaccine (Schonberger et al) 
• Tetanus toxoid 
• Diphtheria toxoid 
• Rabies 
• Oral Polio vaccine 
• Small pox vaccine 
• Meningococcal vaccine 
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• Anthrax vaccine 
6. Serological evidence of specific infectious agents 
• Campylobacter jejuni - 26% 
• Cytomegalovirus - 15% (Visser et al) 
• Human immuno deficiency virus - 1 
• Ebstein - Barr virus - 8% 
• Mycoplasma pneumoniae – 10% 
• Varicella-Zoster virus 
• Hepatitis A and B 
• Hemophilus influenza 
• Childhood Exanthems (Cornblath et al) 
7. Others 
• Drugs – Streptokinase, Suramin, Gangliosides, Heroin 
• Hymenoptera stings 
• Hodgkin’s lymphoma 
• After solid organ or bone marrow transplantation  
• Systemic Lupus Erythematosus 
10 
 
ROSS and BURY’S DIVISION32 
1. Stage of invasion 
2. Progression and plateau phase 
3. Stage of regression 
Paresthesias and slight numbness in the toes and fingers are the earliest 
symptoms1, 3, 4, 5.  The fairly symmetrical weakness of the lower limbs ascends 
proximally over hours to several days to involve arm, facial and oropharyhgeal 
muscles, and in severe cases respiratory muscles - Landry’s ascending paralysis1, 14, 16.  
Trunk, intercostal, neck and cranial muscles are affected later.  Hyporeflexia or 
areflexia are invariable features5, 11, 48.     
Cranial nerve involvement ranges from 45% - 75%48.  Facial paresis1, 9, 22, 48, 
usually bilateral is found in atleast one half of patients. If the weakness of the face is 
out of proportion to that of the limbs, Bannwarth syndrome or Lyme disease should be 
considered5.  Bulbar palsy and weakness of the muscles of mastication are the next 
most common cranial nerve abnormalities31.  Involvement of extraocular muscles 
occurs in 10 percent of patients5. 
Sensory loss is limited frequently to distal impairment of vibration sense and 
joint- position sense (Winer et al 1988)14.  Interscapular or low back pain with 
radiation into the legs is most common and may require short term opiate analgesia5,15.  
Respiratory failure of sufficient severity to require assisted ventilation occurs in 30 
11 
percent of patients, although milder degrees of respiratory muscle involvement are 
much more common.     
Autonomic dysfunction had been reported in 65% of Patients                      
(Zochodne 1994)1, 5, 35,46,48,50 
Signs of decreased sympathetic activity include orthostatic hypotension,                    
anhidrosis.  Signs of increased sympathetic activity include episodic or sustained 
hypertension, sinus tachycardia, tachyarrhythmias, episodic diaphoresis, and acral 
vasoconstriction. 
Signs of decreased parasympathetic activity include urinary retention, 
gastrointestinal atony, iridoplegia.  Signs of increased parasympathetic activity 
include sudden episodes of bradycardia, heart block, asystole. 
ECG changes include T - Wave abnormalities, ST – Segment depression, QRS 
widening, QT prolongation, various forms of heart block. 
Forms of Guillain-Barré Syndrome precipitated by both Campylobacter and 
Cytomegalovirus show delayed recovery compared to cases unassociated with these 
two infections5.  Optic neuritis and pyramidal tract signs are rare manifestations5. 
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AXONAL FORMS 
1. Acute Motor Axonal Neuropathy (AMAN) 
2. Acute Motor Sensory Axonal Neuropathy (AMSAN) 
Axonal forms of Guillain-Barré Syndrome cannot be differentiated form AIDP 
without electrophysiology or extensive pathologic data11, 41.  Most patients with 
AMAN recover as rapidly as patients with AIDP.  Antecedent C. Jejuni infection was 
found in 76% of AMAN patients3, 5, 10.  AMSAN –All patients had a hyperacute 
course, profound quadriparesis and required prolonged ventilator support.  Prognosis 
is unusually poor32, 50. 
DIFFERENTIAL DIAGNOSTIC CONSIDERATIONS1, 8, 12, 48 
1. ACUTE NEUROPATHIES 
Hepatic porphyrias 
Critical illness neuropathy 
Diphtheria 
Toxins 
Arsenic, thallium, organophosphates, lead neurotoxic fish and 
shellfish poisoning (ciguatoxin, tetrodotoxin, saxitoxin) 
Buckthorn 
Tick paralysis 
Vasculitis 
13 
Inflammatory meningoradiculopathies 
Lyme disease 
Cytomegalovirus lumbosacral radiculomyelopathy 
Acute axonal alcoholic polyneuopathy 
2. DISORDERS OF NEUROMUSCULAR FUNCTION 
Botulism 
Myasthenia gravis 
3. MYOPATHIES 
Hypokalemia 
Hyopophosphatemia 
Rhabdomyolysis 
Intensive care Myopathy 
4. CENTRAL NERVOUS SYSTEM DISORDERS 
Poliomyelitis 
West Nile virus poliomyelitis 
Rabies 
Transverse Myelitis 
Basilar artery thrombosis 
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LABORATORY FINDINGS 
CEREBROSPINAL FLUID ANALYSIS 
Cerebrospinal fluid is under normal pressure and is   acellular or contains a few 
lymphocytes, 10 - 50 cells per cubic mm, predominantly lymphocytes1, 39.                       
(albumino – cytological dissociation).  In the first week of neurological symptoms, 
cerebrospinal fluid protein may be normal8; begins to rise with a peak in 4 to 6 weeks 
(100 to 1000 mg/dl) 48.  Persistent pleocytosis suggests an alternative or additional 
diagnosis such as neoplastic meningitis, HIV or Lyme Infection  (Cornblath et al 
1987) 1.   
In 10% of cases, cerebrospinal fluid protein remains normal throughout the 
illness.  The increase in cerebrospinal fluid protein is probably a reflection of the wide 
spread inflammatory disease of the nerve roots1, 12, 23.  Impaired cerebrospinal fluid 
circulation due to increased protein may lead to papilloedeama and pseudotumor 
cerbri (Weiss et al 1991)1, 28. 
ELECTRODIAGNOSTIC STUDIES 
Abnormalities of electrophysiological studies are found in approximately 90% 
of established cases1, 5,6,48. 
The most common abnormalities include24   
1. Prolonged distal motor and F-Wave Latencies. 
2. Absent or impersistent F waves. 
3. Conduction block. 
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4. Reduction in distal CMAP amplitudes with or without temporal 
dispersion. 
5. Slowing of motor conduction velocities. 
Needle EMG48 initially shows decreased motor unit recruitment; if axonal 
degeneration occurs 2 - 4 weeks after onset, fibrillation potentials appear.  
Electrodiagnostic parameters are the most reliable indicators of prognosis.  A distal 
CMAP amplitude of less than 20% of the lower limits of normal was associated with 
poor outcome in the North American Guillain-Barré Syndrome Study. 
  Electro diagnostic studies in acute motor axonal neuropathy include reduced 
CMAP amplitudes, normal motor distal latencies and normal conduction      
velocities5, 24, 48. 
Electro diagnostic studies in acute motor sensory axonal neuropathy include 
markedly reduced or absent CMAPS with distal supramaximal stimulation without 
conduction delay; absent SNAPS, abundant fibrillation potentials, persistently              
inexcitable motor nerves on needle EMG. 
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SEROLOGICAL TESTS12, 48 
Type Antibody Target Usual Isotype 
AIDP GM1  Most common IgG (polyclonal) 
Axonal Variants GD1a, GM1, GM1b, 
GalNAc – GD1a 
(<50% for any) 
IgG (polyclonal) 
MFS GQ1b (>90%)8 IgG (polyclonal) 
Complement fixing antibodies to peripheral nerve myelin P2 are present in 
acute phase of Guillain-Barré Syndrome.  Anti galactocerebroside antibodies are 
present in patients with precedent Mycloplasma infection48. 
OTHERS 
Lumbosacral spinal MRI may demonstrate gadolinium enhancement of the 
cauda equina roots.  Abnormalities of liver function occur in <10% of patients, 
probably reflecting a recent or ongoing viral hepatitis48.  Sedimentation rate is usually 
normal.  Hyponatremia occurs1, 48, especially in ventilated patients due to SIADH or 
excess of atrial natriuretic factor.  Transient diabetes insipidus is rare1.  Deposition of 
immune complexes may rarely lead to glomerulonephritis1. 
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SPECIAL STAINS  
Special stains like Luxol Fast Blue, Immunoperoxidase will show loss due to 
demyelination.  Ultrastructural study through electron microscopy of peripheral nerve 
in Guillain-Barré Syndrome shows presence of mononuclear cells in axons. 
PATHOLOGY 
Virtually all cases of classic Guillain-Barré Syndrome show perivascular 
(mainly perivenons) lymphocytic infiltrates together with multifocal     
demyelination1, 4, 13.  Intense inflammation may lead to axonal degeneration as a 
consequence of a toxic bystander effect1, 48.  The inflammatory infiltrates consist 
mainly of class II – positive monocytes and macrophages and T lymphocytes13.  In 
acute motor sensory axonal neuropathy extensive primary wallerian – like 
degeneration of motor and sensory roots and nerves without significant inflammation 
or demyelination is found (Lu et al, Feasby et al)1,48. 
PATHOGENESIS 
A preceding infection may trigger an autoimmune response through molecular 
mimicry in which the host generates an immune response against an infectious 
organism that shares epitopes with the host’s peripheral nerves1, 5, 12.  Waksman and 
Adams demonstrated that experimentally induced peripheral nerve disease 
(Experimental Allergic Neuritis or EAN) is clinically and pathologically 
indistinguishable from Guillain-Barré Syndrome1, 12, 48.  At the onset of disease, 
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activated T cells play a major role in opening the blood – nerve barrier39.  T – Cell 
activation markers (1L-6, 1L-2, soluble 1L-2 receptor, 1FN-γ), TNF – α are increased 
in serum4 (Hartung et al).  Brostoff and colleagues suggested that the antigen in this 
reaction is a basic protein, designated P2 found only in peripheral nerve myelin1, 12. 
Humoral factors participate in the autoimmune attack on peripheral nerve 
myelin, axons and nerve terminals as evidenced by13, 48 
1. Immunoglobulins and complement can be demonstrated on myelinated fibers. 
2. Miller – Fisher Syndrome and acute motor axonal neuropathy are strongly 
associated with specific antiganglioside antibodies. 
3. Complement C1 – fixing antiperipheral nerve myelin antibody can be detected 
in acute phase. 
4. Plasmapheresis or immunoglobin infusion results in clinical improvement. 
Earliest changes seen within days of onset consisted of deposition of 
complement activation products and membrane attack complex on the outermost 
Schwann cell surface followed by vesicular or myelin changes                       
(Hasfer-Macko et al) 1,5.  Finally macrophages are shown to invade the periaxonal 
space leading to wallerian like degeneration of motor fibres. 
The most attractive candidate targets are GM1 and asialo-GM1 like 
gangliosides, which are present in nodal and internodal membranes of motor fibres34.  
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Acute motor sensory axonal neuropathy may be caused by a more severe immune 
injury triggered by axonal epitopes48. 
COMMON COMPLICATIONS OF GUILLAIN-BARRÉ SYNDROME1, 5, 44, 48 
• Respiratory failure with or without bulbar paresis 
• Dysautonomia 
• Deep vein thrombosis 
• Pulmonary embolism 
• Chest infection 
• Urinary tract infection 
• Ileus 
• SIADH 
• Anxiety neurosis and depression 
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NEUROLOGICAL DISABILITY GRADING IN GUILLAIN-BARRÉ 
SYNDROME (Hughes et al 1978)28, 44 
Grade 0 – Healthy 
       Grade 1 – Minor signs or symptoms of neuropathy but capable of manual work 
       Grade 2 – Able to walk without support but incapable of manual work 
       Grade 3 – Able to walk with a stick, appliance or support 
       Grade 4 – Confined to bed or chair-bound 
       Grade 5 – Requiring assisted – ventilation 
       Grade 6 – Dead 
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MODIFIED DISABILTY GRADING SCALE FOR GUILLAIN-BARRÉ 
SYNDROME (Modified form Hughes et al 1978)28,44 
Grade 0 – Healthy 
       Grade 1 – Minor signs or symptoms  
       Grade 2 – Able to walk 5 meters without support 
       Grade 3 – Able to walk 5 meters with a stick, appliance or support 
Grade 4 – Confined to bed or chair-bound (unable to walk 5 meters with  
       support)   
       Grade 5 – Requiring assisted – ventilation (for atleast part of the day) 
       Grade 6 – Dead 
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TREATMENT  
GENERAL MEDICAL ASPECTS 
Supportive care and prevention of complications in intensive care units, of 
which respiratory failure and autonomic dysfunction are the most important, provide 
the best chance for a favorable outcome.  During the progressive phase, respiratory 
and bulbar function, the ability to handle secretions, heart rate and blood pressure 
should be closely monitored1, 20.  
Respiratory failure requiring mechanical ventilation develops in upto 30% of 
patients with Guillain-Barré Syndrome.  The mortality has fallen from 33% before 
introduction of positive pressure ventilation to the current rate of approximately        
5-10% 48. 
Signs of impending respiratory failure include36, 48 
 
1.  Deterioration in Forced Vital Capacity (FVC) 
2. Declining maximal respiratory pressures 
3. Tachyponea and decrease in arterial oxygen tension (PO2 < 85mm Hg)   
reflecting pulmonary atelectasis 
The strength of the neck muscles and trapezii, which share the same segmental 
innervations as the diaphragm, tends to parallel diaphragmatic strength.   Ability to 
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reach 20 by single breath count generally corresponds to a vital capacity of greater 
than 1.5 L. 
Predictors of future need of mechanical ventilation1, 5, 48 
 
1. Rapid disease progression (onset to admission in less than 7 days) 
2. Bulbar dysfunction 
3. Bilateral facial paresis 
4. Autonomic instability 
Predictors of future respiratory failure 20 - 30 – 40 rule48 
1. Vital capacity of less than 20 ml/kg or a decline by 30% from baseline 
2. Maximal inspiratory pressure less than 30cm of H2O 
3. Maximal expiratory respiratory pressure less than 40cm of H2O 
Elective intubation should be performed when17, 48, 49 
1. FVC falls below 12-15 ml/kg 
2. FVC falls below 18 ml/kg with severe oropharyngeal weakness 
3. Arterial PO2 values <70mmHg with inspired room air 
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Indications of tracheostomy1, 5 
1. When the need for mechanical ventilation > 2 weeks 
2. Failure to clear the tracheobronchial air ways effectively 
With tracheostomy and intensive care, the mortality from disease can be 
reduced to about 3% (Ropper and Kehne) 48.  During intubation, succinyl choline is 
not preferable due to upregulation of acetylcholine receptors on denervated muscles 
may causes lethal hyperkalemia2.  Nondepolarizing agents may be problematic 
because of resistance and increased sensitivity.  Etomidate is preferred, if oral 
intubation is done, because of the inherent hemodynamic stability. 
OTHER MEASURES 
Hypotension from dysautonomia is treated by intravenous volume infusion and 
by the use of vasopressor agents for brief periods1.  Extremes of hypertension are 
managed by short-acting and titratable antihypertensive medications such as 
intravenons labetolol1. 
Prevention of electrolyte imbalance, gastrointestinal hemorrhage, noscomial 
infections     are important in intensive care.  Deep venous thrombosis and pulmonary 
embolism can be prevented by the use of subcutaneous heparin, low molecular weight 
heparin and calf compression devices1, 12, 30. 
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Exposure keratitis is avoided by using artificial tears.  Pressure – induced ulnar 
or fibular nerve palsies are prevented by proper positioning and padding.  Physical 
therapy1,18 is started early because it helps prevent contractures, joint immobilization 
and venous stasis.  Psychological support and constant reassurance are essential45. 
SPECIFIC THERAPEUTIC INTERVENTIONS 
Immunomodulation has been used to enhance recovery and avoid 
complications of Guillain-Barré Syndrome28 
Treatment modalities include 
1. Plasma exchange  
2. Intravenous immunoglobulin therapy 
SELECTION CRITERIA28 
1. Time lapse between disease onset and assessment of the patient. 
2. Disease severity. 
3. Rate of disease progression. 
Should be done as early as possible preferably during the first week.  Patients 
with mild symptoms, slow or lack of disease progression do not require 
immunomodulation. 
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INDICATIONS 
Patients who  
1. Are unable to walk unassisted 
2. Have bulbar paralysis 
3. Are on the verge of respiratory failure or require ventilator assistance 
4. Shows rapid disease progression within two weeks of disease onset 
PLASMA EXCHANGE – ADVANTAGES1, 5, 12,28,44,48 
1. Rapid onset of action 
2. Usually safe and well tolerated 
3. Few side effects 
4. Effective in two-third of cases 
5. Hastens recovery and the time taken to improve one clinical grade 
(Guillain-Barré Syndrome Study Group 1985) 
6. Shortens the time on ventilator and decreases the chances of becoming 
ventilator dependent 
7. Improves the poor prognostic factors 
8. Decreases the percentage of cases with residual disability at 6 months 
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Predictors of responsiveness to plasma exchange treatment are the patient’s age 
(young) and the preservation of CMAP amplitudes prior to instituting treatment1, 47.  
The advised regimen of plasma exchange removes a total of 200 – 250ml/kg of 
plasma in four to six treatments on alternate days.  The replacement fluid is saline 
combined with 5% albumin. 
COMPLICATIONS AND SIDE EFFECTS1, 28, 44 
1. Hemodynamic and cardiovascular 
 Hypotension 
 Acute respiratory distress syndrome 
 Acute Cardiac Insufficiency 
 Myocardial infarction 
 Arrhythmias 
2. Complications due to vascular access 
 Septicemia 
 Thrombosis   
3. Associated with replacement fluids / anticoagulants 
 Allergic reactions 
 Hepatitis, HIV (FFP) 
 Citrate toxicity 
28 
 Bleeding 
4. Depletion of Plasma Components 
 Loss of clotting factors, globulins 
 Loss of protein – bound drugs 
5. Technical Complications 
 Clotting in the tubing 
 Air embolism 
 Haemolysis 
 Death (0-0.3%) 
INTRAVENOUS IMMUNOGLOBULIN THERAPY 1, 12, 35,44,46,48 
IVIG contains normal polyvalent immunoglobulin G, derived from a large 
number of blood donors.   
Possible mode of action of IVIG includes 
1. Anti-idiotypic antibody effect 
2. Blockade of Fc receptors on macrophages (interferes with antibody 
dependent cellular cytotoxicity) 
3. Down regulation of immunoglobulin production 
4. Down regulation of B Cells (CD5 +B Cells by anti CD5 antibodies) 
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5. Inhibition or attenuation of cytokine actions by anticytokine antibodies 
6. Interference with T cell activation 
7. Induction of T suppressor cells 
8. Inhibition or neutralization of complement mediated effects 
9. Virus neutralization 
Safe in patients as young as 2 years to as old as 93 years of age43.  Should be 
avoided in pregnancy.  Miller Fisher Syndrome and Acute Pandysautonomia also 
respond to IVIG28.  
DOSE AND MODE OF ADMINISTRATION1, 5, 12, 28 
• Adults – 400 mg/kg/day for 5 consecutive days, children- 1gm/kg/day for 2 
days. 
• Half - life of IVIG is around 23 days. 
• Its beneficial effect may last for 2-9 weeks. 
COMPLICATIONS AND SIDE EFFECTS1,12,28,44 
• Headache including precipitation of migraine 
• Back pain 
• Fever 
• Tachycardia 
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• Aseptic meningitis 
• Rash (Erythema multiforme, purpuric erythema, maculopapular, petechial) 
• Alopecia 
• Eczema 
• Reversible neutropenia 
• Hemolysis 
• Immune complex arthritis 
• Thromboembolism 
• Transmission of hepatitis C Virus 
• Deep venous thrombosis 
• Congestive cardiac failure 
• Acute hypotension 
• Oligaemic renal failure 
• Cerebral vasospasm 
• Anaphylaxis – in IgA deficient individuals 
ADVANTAGES OF IVIG1, 40, 44 
• Wide availability 
• Does not require special equipment 
• Can be given at any center 
• Easily administered 
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• Can be used with ease in small children and aged patients with limited access  
or other contraindications for plasma exchange 
• Few side effects 
• No risk of HIV 
• Rapid response  
• Equally effective or slightly superior to PE 
• 75% cases show good response to treatment 
PLASMA EXCHANGE VS IVIG THERAPY28 
Both PE and IVIG have emerged as equally effective treatment options in 
Guillain-Barré Syndrome.  Around 66 – 75% patients respond. 
IVIG is often preferred as the first line agent in children, elderly, Guillain-
Barré Syndrome variants like MFS, Acute pandysautonomia, Guillain-Barré 
Syndrome with prominent sensory ataxia, pure motor forms. 
COMBINED USE OF PE AND IVIG28, 48   
PE and IVIG have precisely opposite effects.  The body pool of 
immunoglobulins is depleted by PE and expanded by IVIG.  Combined PE and IVIG 
may have a synergistic effect. 
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IVIG administration immediately after PE may prevent a rebound antibody 
synthesis to peripheral nerve myelin following removal of immunoglobulins and 
antibodies by PE28.   
2 recent studies using combined PE and IVIG therapy have observed only a 
slight increase in efficacy with the combined approach as compared to the use of IVIG 
or PE alone.  Above two treatments can be repeated if a patient is clearly declining 
particularly if there is evidence of mainly demyelinating disease on the EMG and if 
the illness is not much longer than 3 weeks duration.  
ROLE OF CORTICOSTEROIDS 
Two randomized controlled studies, one with conventional - dose prednisolone 
and the other with high dose methylprednisolone have failed to demonstrate any 
beneficial effect15, 28, 47   (Guillain-Barré Syndrome steroid trial group 1993).  Steroids 
might increase the subsequent relapse rate (Hughes et al 1978). 
ROLE OF GABAPENTIN28 
Gabapentin, an antiepileptic drug, has been used effectively for different types 
of pain management. This study demonstrates that gabapentin has minimal side effects 
and is an alternative to opioids and NSAIDS for management of the bimodal nature of 
pain of Guillain-Barré Syndrome patients. 
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COURSE AND PROGNOSIS 
By definition, patients should reach their maximum deficit within 4 weeks of 
onset, if the disease progresses for longer, it is classified as subacute or chronic 
inflammatory demyelinating polyradiculoneuropathy (SIDP, CIDP)27,29. 
Upto 30% of patients develop respiratory insufficiency and between 2-5% die 
of complications10.  
70% of patients complete their recovery in 12 months8, 12, 82% in 24 months. 
20% have still residual motor weakness 1 year later1. 
About 3% of patients may have a recurrence following recovery. 
As a rule, older adults recover more slowly than younger ones and children and 
have more residual weakness1, 37. 
Poor Prognostic Factors (North American Guillain-Barré Syndrome study        
group) 5, 42, 48 
1) Older age > 60 years 
2) Preceding diarrhoeal illness 
3) Respiratory failure requiring ventilatory support 
4) Rapid progression reaching maximum deficit in less than 7 days 
5) Low amplitudes of distal CMAPS (20% of lower limit of normal or less) 
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6) Extensive spontaneous fibrillation in distal muscles indicating 
denervation 
The mortality is 4 – 5% even for patients treated in specialist neurological units 
with PE or IVIG (PE / Sandoglobulin GBS trial group 1997)33. 
CAUSES OF DEATH1,5 
EARLY STAGES     
    
 Cardiac arrest due to dysautonomia 
 Adult respiratory distress syndrome  
 Pneumothorax 
 Hemothorax 
 Accidental machine failure 
LATE STAGES 
 
 Pulmonary embolism 
 Medical complications of prolonged immobilisation 
 Respiratory failure 
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RELAPSING FORMS 
Recurrent Guillain-Barré Syndrome occurs in up to 3%, after an interval of 
many years (Loffel et al 1977)1,5.  It may be due to a cyclic dysimmune state of the 
host or unidentified triggering factors acting on a vulnerable host. 
The episodes may be precipitated by new infection, such as recurrent 
cytomegalovirus exposure (Donaghy et al 1989) or two different infections such as 
respiratory syncytial virus and campylobacter jejuni (Hayashi et al 1993) or booster 
vaccinations with tetanus toxoid5, 48. 
  Relapsing forms of Guillain-Barré Syndrome can be distinguished from 
relapsing forms of CIDP by the rapidity of onset, the marked degree of recovery, 
normal CSF protein at the onset of an attack, the high incidence of preceding 
infections and the lack of response to immunosuppressant drugs (Grand’Maison et al 
1992)5.               
The Guillain-Barré Syndrome Association of New South Wales is a 
registered charity that provides information and support to those affected by Guillain-
Barré Syndrome, CIDP, and related conditions.  
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MILLER-FISHER SYNDROME 
The Miller-Fisher syndrome which accounts for 5% of Guillain-Barré 
Syndrome cases25, 32, is characterized by ophthalmoplegia, ataxia and areflexia.  
Patients present with diplopia followed by gait and limb ataxia. Ocular signs range 
from complete ophthalmoplegia, including uncreative pupils, to external 
opthalmoparesis with or without ptosis.  Cranial nerves other than ocular motor nerves 
may be affected31. 
Motor strength is characteristically preserved21.  The ataxia is attributed to a 
peripheral mismatch between propriceptive input from muscle spindles and 
kinesthetic information from joints receptors48.  Patients presents with rapid onset of 
symmetrical, multiple cranial nerve palsies, most notably bilateral facial palsy 
(polyneuritis cranialis) 42, that may be a forme fruste of this syndrome. 
Electrodiagnostic studies demonstrate an axonal process affecting 
predominantly sensory fibres with only mild motor conduction abnormalities32.  
Sensory nerve action potential amplitudes are usually normal.  
MFS has a benign prognosis, with recovery after a mean of 10 weeks26. 
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FUTURE THERAPIES28, 38, 42 
Immunomodulatory treatment in the future may utilize recombinant cytokines 
(eg. Interlenkin-10, tumor growth factor, interferon-beta) and antibodies to 
inflammatory cytokines (eg. Tumor necrosis factor-alpha, soluble cytokine receptors 
or cytokine antagonist). 
Treatment with P2 protein peptide 57-81, by nasal route has been found to be 
effective in rat experimental allergic neuritis.  Sodium Fusidate which suppresses 
interlenkin-2, interferon and tumor necrosis factor-alpha both in vitro and in vivo also 
holds promise. 
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MATERIALS AND METHODS 
Guillain-Barré Syndrome is a monophasic illness; often it is self-limiting. The 
initial assessment was based on clinical history, detailed neurological examination, 
routine investigations and special investigations like cerebrospinal fluid analysis and 
electrodiagnostic studies. 
SELECTION OF PATIENTS 
INCLUSION CRITERIA 
1. Any patient admitted with features suggestive of flaccid progressive weakness 
affecting all the four limbs were included 
2. Any patient admitted with progression of weakness of less than 4 weeks 
duration were included. 
3.  Any patient admitted with reduced or absent deep tendon reflexes were 
included 
EXCLUSION CRITERIA 
1. Any patient admitted with features of hypokalemic periodic paralysis. 
2. Any patient admitted with features of upper motor neuron signs and symptoms 
3. Any patient admitted with severe protopathic sensory symptoms         
4. Any patient admitted with history of bite preceding the illness     
5. Any patient admitted with history of exposure to toxins like organophosphates 
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6. Any patient with severe terminal illness 
7. Patients admitted with history of suspected food poisoning 
8. Patients in whom the weakness progressed for more than 4 weeks 
Number of cases studied: 50   
Duration of study: December 2005 – January 2007 
Detailed neurological examination including higher mental functions, cranial 
nerves, motor system, sensory system and autonomic system was done for all 50 
patients. Motor power in these patients were assessed according to Medical Research 
Council grading. 
Autonomic dysfunction was looked for in all these patients. History of dryness 
of mouth, postural giddiness and defective sweating over the body were specifically 
asked for.    
Blood pressure was routinely taken in lying and sitting posture and if possible 
in standing posture to bring out orthostatic hypotension. Sympathetic skin response 
was not done due to technical problem.  
Respiratory function tests were done in all patients, everyday during 
hospitalization, including breath-holding time, single breath count, blowing candle at 
one arm length, chest expansion, Litten’s phenomenon. 
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Likewise, basic investigations like complete blood count, peripheral smear, 
blood sugar and urea, serum creatinine and electrolytes, erythrocyte sedimentation 
rate, daily electrocardiogram, chest x-ray were done for all the 50 patients. 
Lumbar puncture was done for 42 patients and CerebroSpinal Fluid was sent 
for Gram’s stain, biochemical and cytological analysis. 
Electrophysiological studies were conducted by using the machine RMS 
ADVANCE TESTING LAB.  Nerve conduction studies were done in both upper and 
lower limbs. 
In upper limbs, proximal latency, distal latency, motor nerve conduction 
velocity, F-response were studied in ulnar, median and radial nerves. 
In lower limbs, similarly proximal latency, distal latency, motor nerve 
conduction velocity, F-response, H -reflex were studied in sciatic, lateral 
popliteal and posterior tibial nerves. 
Sensory conduction velocity were studied in median nerve, ulnar nerve 
and sural nerve.  
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Electromyography was done with surface electrodes in thenar and hypothenar 
muscles, quadriceps, calf muscles, extensor digitorum.  
Insertional activity was recorded. 
Resting activity was recorded. Fibrillation potential, fasciculation 
potential, positive sharp waves were looked for. 
Recruitment and interference pattern were looked for.  
Compound muscle action potential was recorded. 
Magnetic Resonance Imaging was done in 4 patients who presented with 
altered sensorium, sensory disturbance and urinary retention.                   
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OBSERVATION AND RESULTS 
SEX INCIDENCE 
In the 50 patients studied, 30 were male and 20 were female.  
TABLE 1 
SEX NO. OF PATIENTS PERCENTAGE 
Male 30 60% 
Female 20 40% 
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AGE INCIDENCE 
All the 50 patients were above the age of 15; among which 26 (52%) patients 
were below the age of 40, 15 patients (30%) were between 40-60years,                       
9 patients (18%) were above the age of 60.  
TABLE 2 
AGE IN YEARS NO.OF PATIENTS PERCENTAGE 
< 40 26 52% 
40-60 15 30% 
> 60 9 18% 
26
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15
30%
9
18%
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15
20
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< 40
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CO-EXISTING MEDICAL ILLNESS 
4 patients were on treatment for diabetes mellitus, 3 patients were on treatment 
for hypertension, 2 patients were on treatment for pulmonary tuberculosis and 
ischemic heart disease.  
TABLE 3 
Sl.No ILLNESS NO. OF PATIENTS PERCENTAGE 
1 DM 4 8% 
2 SHT 3 6% 
3 CAHD 2 4% 
4 PT 2 4% 
4
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ANTECEDENT EVENTS 
7 patients gave history of upper respiratory tract infection preceding the 
neurological illness.  5 patients gave history of gastroenteritis preceding the illness.     
1 patient gave history of vaccination for dog bite preceding the illness. 
1 patient was reactive for HIV.  1 patient was found to have generalised 
lymphadenopathy and mild hepatosplenomegaly, and Fine Needle Aspiration 
Cytology proved to be Hodgkin’s lymphoma.  
 TABLE 4 
Sl.No. ANTECEDENT EVENTS NO.OF PATIENTS PERCENTAGE
1 RESPIRATORY ILLNESS 7 14% 
2 GASTROINTESTINAL 
ILLNESS 5 10% 
3 VACCINATION 1 2% 
4 HODKIN’S  LYMPHOMA 1 2% 
5 HIV 1 2% 
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CLINICAL PRESENTATION 
In 50 patients studied, 42 patients had weakness of both upper and lower limbs; 
15 patients had neck muscle weakness; 8 patients had features suggestive of bulbar 
weakness; 2 patients had ocular muscle involvement. 
15 patients gave history suggestive of sensory disturbance and 12 patients had 
electrophysiological evidence of sensory involvement. 7 patients had bilateral lower 
motor neuron type of facial weakness. 
4 patients developed altered sensorium for a short period with complete 
recovery within days. 
 
 
 
 
 
 
48 
 TABLE 5 
Sl. No. 
CLINICAL     
PRESENTATION 
NO.OF 
PATIENTS 
PERCENTAGE 
1 
WEAKNESS OF BOTH 
UPPER AND LOWER 
LIMBS 
42 84% 
2 
AUTONOMIC 
DYSFUNCTION 
20 40% 
3 
RESPIRATORY 
MUSCLE WEAKNESS 
15 30% 
4 
NECK MUSCLE 
WEAKNESS 
15 30% 
5 BULBAR WEAKNESS 8 16% 
6 
BILATERAL FACIAL 
WEAKNESS 
7 14% 
7 
SENSORY 
DISTURBANCE 
15 30% 
8 ALTERED SENSORIUM 4 8% 
9 
OCULAR MUSCLE 
INVOLVEMENT 
2 4% 
10 ATAXIA 1 2% 
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Among these 50 patients, 15 patients developed respiratory distress in some 
form and 5 of them were provided ventilator for life support.  3 out of the 5 patients 
on ventilator died without improvement.  Remaining 2 patients were weaned from 
ventilator after 4 days with favorable outcome. 
2 patients died due to respiratory distress, before giving ventilatory support.     
3 patients who developed severe respiratory distress were discharged as against 
medical advice and follow up was not recorded. 
20 patients presented with some form of autonomic dysfunction.  Orthostatic 
hypotension was found in 8 patients.  Cardiac arrhythmias in electrocardiogram 
including ventricular, atrial ectopics, sinus tachycardia and ST-T changes were noted 
in 7 patients.  Remaining 5 patients had features of bladder disturbance in the form of 
urinary retention in whom catheterisation was done. 
Among 15 patients who had respiratory distress, 11 patients showed autonomic 
disturbance.  All patients who expired and who were on ventilator had autonomic 
disturbance. 
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CEREBROSPINAL FLUID ANALYSIS 
Cerebrospinal fluid analysis was done for 42 patients. Cerebrospinal fluid     
protein was increased in all the 42 patients ranging from 260mgs% to 1.5gms%. 
Cerebrospinal fluid cell count was within normal limits, i.e. less than 50 mononuclear 
cells per cubic millimeter.  Cell count was 250 in one patient with HIV infection. 
TABLE 6.1 
 
    CELL COUNT 
per cubic mm 
< 10 10-20 21-30 31-40 41-50 >50 
NO.OF PATIENTS 5 9 19 7 1 1 
0
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TABLE 6.2 
 
PROTEIN (mgs %) 200-400 401-600 601-800 800-1000 >1000 
NO.OF PATIENTS 7 10 9 9 7 
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All these 50 patients had abnormal electrodiagnostic studies like 
1. Motor Nerve Conduction Velocity was decreased in all the 4 limbs 
varying from mild to severe degree. 
2. Conduction block was present in 6 patients. 
3. H- reflex could not be elicited in all the patients. 
4. F- response was prolonged in 8 patients and absent in 42 patients. 
5. Compound Muscle Action Potential was decreased in more than 40 
patients. 
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ELECTRODIAGNOSTIC STUDIES 
NERVE CONDUCTION STUDIES UPPER LIMBS 
TABLE 7  
SL.
NO 
 
NO. OF 
PATIENTS 
ULNAR MEDIAN RADIAL 
37 Prolonged Prolonged Prolonged 
1 Proximal latency 
5 Normal Normal Normal 
40 Prolonged Prolonged Prolonged 
2 Distal latency 
2 Normal Normal Normal 
36 Delayed Delayed Delayed 
3 MNCV 
6 Normal Normal Normal 
30 Absent Absent Absent 
4 F-Response 
12 Prolonged Prolonged Prolonged 
5 SNCV 12 Absent Absent - 
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NERVE CONDUCTION STUDIES LOWER LIMBS 
TABLE 8  
SL.
NO 
 
NO. OF 
PATIENTS 
COMMON 
PERONEAL 
POSTERIOR 
TIBIAL 
SURAL 
40 Prolonged Prolonged 
1 
Proximal latency 
10 Normal Normal - 
45 Prolonged Prolonged 
2 
Distal latency 
5 Normal Normal - 
43 Delayed Delayed 
3 
MNCV 
7 Normal Normal - 
42 Absent Absent 
4 
F-Response 
8 Prolonged Prolonged - 
5 H-Reflex 50 Absent Absent - 
6 SNCV 12 - - Absent 
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The disease progressed in 40 patients upto 14 days.  35 patients worsened in 
the first week.  15 patients worsened after the first week.  
40 patients had shown some improvement during hospital stay itself.               
10 patients did not show any improvement during hospital stay.  Among 40 patients in 
whom improvement had seen, recovery was rapid during the first week in 35 patients.  
Cerebrospinal fluid analysis and electrodiagnostic studies were done only once 
during their hospital stay and follow up study could not be done.   
Magnetic resonance imaging was done in 4 patients which showed no evidence 
for cord compression or myelitis. 
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TYPES OF GUILLAIN-BARRÉ SYNDROME 
TABLE 10 
S.NO TYPES NO.OF 
PATIENTS 
PERCENTAGE 
1. AIDP 25 50% 
2. AMAN 12 24% 
3. AMSAN 10 20% 
4. MFS 1 2% 
5. SENSORY GBS 2 4% 
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OUTCOME OF PATIENTS 
TABLE 11 
S.NO OUTCOME NO.OF. PATEINTS PERCENTAGE
1 SPONTANEOUS RECOVERY 40 80% 
2 RESPIRATORY FAILURE 15 30% 
3 AUTONOMIC DISTURBANCE 20 40% 
4 VENTRICULAR ARRHYTHMIAS 7 14% 
5 MORTALITY 5 10% 
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DISCUSSION 
50 patients were included in our study. The incidence of Guillain-Barré 
Syndrome was around 1% in total hospital admissions in neurology ward.                                           
Sex prevalence in our study was 60% (30) for men and 40% (20) for women.  
Seasonal variation was observed in our study, between July and October. This 
observation is supported by reports from India and China.  
Among the 50 patients studied, 52 % (26) of patients were below 40 years, 
30% (15) of patients were between 40-60 years and 18% (9) of patients were above 
the age of 60.  The age range of our consecutive patients has been 16 years to 78 
years, with attack rates highest in persons less than 50 years of age. 
 Those patients with coexisting illness like diabetes mellitus, systemic 
hypertension, ischemic heart disease and pulmonary tuberculosis were above the age 
of 40 and they had delayed recovery.  Approximately one third of patients reported a 
history of an antecedent event. According to the study by Rees et al, 1995 preceding 
diarrhoeal illness, especially Campylobacter jejuni infection was documented in cases 
of acute motor axonal neuropathy; supporting our study. 
  
60 
30% (15) of patients developed respiratory muscle weakness in some form. 
Diaphragmatic movement was assessed by Litten’s phenomenon. Diaphragmatic 
weakness was increased during the second week and began to recover after the third 
week.  
In patients with respiratory distress, need for ventilatory support was assessed 
by respiratory rate, single breath count, chest expansion, oxygen saturation and 
appearance of central cyanosis. In a study by Sharshar et at, 2003, short disease 
duration, inability to lift the head, and a vital capacity of less than 60% predicted the 
need for mechanical ventilation in 85% of patients.  Accordingly, 10% (5) of our 
patients were put on ventilator.  
Autonomic dysfunction was observed in 40% (20) of patients.  Orthostatic 
hypotension was detected in 8 patients; Abnormal sweating either increased or 
decreased sweating was looked for in the trunk and limbs.  Arrhythmias were found in 
7 patients.  Benign arrhythmias like ventricular and atrial ectopics, and non specific 
ST-T changes, sinus tachycardia, less often sinus bradycardia were noted in 5 patients, 
which persisted for less than a week.  Fatal ventricular arrhythmias were found in 2 
patients. 
   In a study by Zochodne et al in 1994, autonomic dysfunction was observed in 
65% of patients and in another study by Winner and Hughes in 1998, cardiac 
arrhythmias due to autonomic dysfunction was the leading cause of death, which 
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contributed by 7 percent.  As per the above study major causes of death in our study 
were due to respiratory failure and cardiac arrhythmias.   
Most of the patients with respiratory failure were found to have autonomic 
dysfunction and recovery was delayed. Mortality was increased in patients who have 
combined respiratory failure on ventilatory support and autonomic dysfunction, 
especially orthostatic hypotension and ventricular arrhythmias. 
  Bladder disturbance was one of the clinical presentations in 5 patients, all of 
them were above the age of 60 for whom catheterisation was not needed for more than 
a week. 
15 patients had sensory disturbance in the form of impaired position and 
vibration sense. Study by Winner et al in 1998 support this study.  12 patients were 
found to have sensory involvement on electrodiagnostic studies.   
Most of the studies do not recommend the use of steroids.  Yet many centers 
use high dose oral prednisolone or methylprednisolone.   In our hospital, we do not 
use steroids routinely, some patients included in our study, had been treated with 
steroids outside.   
6% (3) of patients on steroids developed peptic ulceration and gastrointestinal 
bleeding, with delayed recovery. 
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2% (1) of patients with diabetes mellitus who were put on steroids developed 
ketoacidosis and turned out with delayed recovery. 
In our study, there was no significant difference in the outcome of patients 
treated with or without steroids, similar to the word literature.   A randomized trial of 
oral prednisolone therapy by Guillain-Barré Syndrome steroid trial group in 1993, 
showed no benefit. A study by Hughes et al 1978, suggested that steroids might 
increase the subsequent relapse rate. 
Those patients above the age of 60 without any medical illness also, showed 
delayed recovery. The North American Guillain-Barré Syndrome study group support 
our study. 
4% (2) of the patients presented with ocular muscle involvement; 2% (1) of the 
patients had ataxia, with favorable outcome. 
Prognosis in patients with Guillain-Barré Syndrome varied linearly with 
severity of demyelination or axonal degeneration detected by electrodiagnostic 
studies. 
Recovery was delayed in patients with conduction block than in patients with 
delayed motor nerve conduction velocity alone. 
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Recovery was earlier and favorable in patients with absent H-reflex and F-
response and delayed motor conduction than in patients with conduction block.          
A distal CMAP amplitude of less than 20% of the lower limits of normal was 
associated with poor outcome in the North American Guillain-Barré syndrome study 
group.    
In our study, mortality was around 10 percent.   Commonest cause of mortality 
were respiratory failure and ventricular arrhythmias. 
Patients with high protein content in cerebrospinal fluid indicating 
demyelination of nerve roots showed delayed recovery. 
In a study by Ropper and Marmarou, the increase in cerebrospinal fluid protein 
had no clinical or prognostic significance. 
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CONCLUSION 
1. The incidence of Guillain-Barré Syndrome in our study was around 1% among 
total hospital admissions in neurology ward. 
2. There was no significant sex preponderance in our study.  
3. 80% of Guillain-Barré Syndrome patients recovered smoothly without going 
for complications. 
4. 10% of patients developed bulbar weakness of varying severity. 
5. 30% of patients developed neck muscle weakness of varying severity. 
6. 30% of Guillain-Barré Syndrome patients developed respiratory muscle 
weakness of varying severity. 
7. 10% of patients needed ventilatory support to maintain oxygen saturation. 
8. 40% of patients showed features of autonomic disturbance of varying severity. 
9. 2 patients had features suggestive of ocular muscle involvement and in              
1 patient features of incordination was present. 
10. Prognostic outcome in our study is somewhat poor with increasing age. 
11. Prognostic outcome is poor when there is co-existing illness like diabetes      
mellitus or ischemic heart disease. 
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12. Cerebrospinal fluid analysis in patients the Guillain-Barré Syndrome who had 
increased protein correlated with severe demyelination in electrodiagnostic 
studies and delayed recovery 
13. Prognosis in patients the Guillain-Barré Syndrome linearly varies with   
severity of electrodiagnostic studies. 
H-reflex was invariably absent  in all those patients included in the   study. 
F- response was absent in 90% of patients  in lower limbs and 70% of 
patients  in upper limbs. 
Reduction in motor nerve conduction velocity was noted in all these 
patients of varying severity. 
A feature of conduction block was noted in patients with severe weakness. 
Recovery was delayed in patients with conduction block than in patients 
with delayed motor nerve conduction velocity alone. 
14. In our study, there was no significant difference in the outcome between 
patients treated with or without steroids. 
15. Mortality was around 10% in our study. 
16. The commonest cause of mortality was respiratory failure and fatal ventricular 
arrhythmias. 
 
I 
 
BIBLIOGRAPHY 
1. ADAMS and VICTOR’S – Principles of Neurology – Eighth Edition,               
P -1121-1127. 
2. ALLAN H-ROPPER Neurological and Neurosurgical intensive care – Fourth 
Edition, P -278-295. 
3. ANDREOLI, CARPENTER, GRIGGS, LOSCALZO-CECIL Essentials of 
Medicine – sixth Edition, P -1078, 1080. 
4. ASBURY, MCKHANN, MCDONALD, GOADSBY, MCARTHUR-Diseases 
of the Nervous system, Third Edition, Volume-2, P-1110 – 1114. 
5. BRAIN’S Neurology, 11th Edition, P-357-365. 
6. BROWN BOLTON, MICHAEL J. AMINOFF-Neuromuscular function and 
diseases, volume1,first edition, p-65-66,1042,1051 
7. JS. CHOPRA and IMS SAWHNEY- Neurology in Tropics-First Edition,                   
P - 353,624,631. 
8. DAVIDSON’S Principles and Practice of Medicine - 20th Edition, P- 1249-
1250 
9. ERIC R.KANDEL, JAMES H.SCHWARTZ, THOMAS M. JESSELL - 
Principles of Neural Science- Fourth Edition, P-82, 702. 
10. FRED F. FERRI-FERRI’S Clinical Advisor-Instant Diagnosis and Treatment, 
2004 Edition, P-376. 
11. GOLDMAN, AVSIELLO-CECIL Textbook of Medicine, Twenty second 
Edition, Volume 2 - P-2379-2380. 
II 
 
12. HARRISON’S Principles of Internal Medicine-16th Edition- Volume 2,           
P- 2513-2516 
13. HARSH MOHAN-Textbook of Pathology-Fifth Edition, P-919 
14. HARWOOD-NUSS’S Clinical practice of Emergency Medicine, Fourth 
Edition,     P-737-738,1250-1251 
15. ILKKA KUNNAMO, Evidence-based Medicine Guidelines, P-1182-1183 
16. JAMES W. LANCE. A physiological Approach to Clinical Neurology-Second 
Edition, P-39,59,64 
17. JOAN E. DAVIS, CELESTINE B. MASON-Neurologic Critical care-First 
Edition,        P-227-228. 
18. MARGARET R. SEIDEN, Practical Management of Chronic Neurologic 
Problems, First Edition, P-348-350. 
19. MARK MUMENTHALER-Neurology-Fourth Revised Edition, P-575-578. 
20. MARSCHALL S.RUNGE, M. ANDREW GREGANTI-NETTER’S Internal 
Medicine, P-694,699. 
21. W. B. MATTHEWS, HENRY MILLER-Diseases of the Nervous System, First 
Edition, P-200-202. 
22. MERRITT’S Neurology-Tenth Edition, P-613-615. 
23. MICHAEL J. AMINOFF – Clinical Neurology, Sixth Edition, P - 212, 213. 
24. MICHAEL J. AMINOFF - Electrodiagnosis in Clinical Neurology- Fifth 
Edition,    P - 305, 365, 418, 419, 745. 
25. MICHAEL J. AMINOFF –Neurology and General Medicine – Third Edition,           
P -733-734, 1011-1012. 
III 
 
26. NELSON Textbook of Pediatrics – 17th Edition, P-2080, 2081. 
27. NEUROSCIENCES Today, Volume No.1, January – March 2001, 
Management strategies in Guillain-Barré Syndrome – Geeta A. Khwaja,          
P-22-31. 
28. NEIL SCOLDING – Contemporary Treatments in Neurology – First Edition,           
P-147-154. 
29. OXFORD Textbook of Medicine – Fourth Edition, Volume 3, P -1190, 1191. 
30. PARVEEN KUMAR, MICHAEL CLARK, Clinical Medicine, Sixth Edition,                    
P-1260-1261. 
31. PAUL W. BRAZIS, JOSE C. MASDEU, JOSE BILLER – Localization in 
Clinical Neurology –Fifth Edition, P -238, 295, 300, 329. 
32. PETER J.DYCK and P.K THOMAS-Peripheral Neuropathy-Fourth Edition-
Volume 2, P-2197-2213. 
33. RAKEL and BOPE-CONN’S Current Therapy-2006, P-1000-1001. 
34. RANDOLPH W.EVANS, Diagnostic Testing in Neurology - P-276,358. 
35. RANDOLPH W.EVANS, SAUNDERS Manual of Neurologic Disease First 
Edition, P-572-575. 
36. RICHARD V.AGHABABIAN, Emergency Medicine -The Core Curriculum, 
P-542-544. 
37. RICHARD S. IRWIN, JAMES M.RIPPE, Manual of Intensive care Medicine, 
Fourth Edition, P-760-763. 
38. RICHARD T.JOHN, W.GRIFFIN, JUSTIN C.MCARTHUR, Current Therapy 
in Neurologic Disease, Sixth Edition, P-366, 370. 
IV 
 
39. ROBBINS AND COTRAN - Pathologic Basis of Disease, Seventh Edition,    
P-1331. 
40. ROBERT E.RAKEL - Saunders Manual of Medical Practice, Second Edition, 
P-1388, 1396 - 1397. 
41. ROPPER AH: The Guillain-Barré Syndrome-New England Journal of 
Medicine 326; 1130, 1992. 
42. H.ROYDEN JONES. Jr, DARRYL C.DEVIVO, BASIL T. DARRAS-
Neuromuscular Disorders of Infancy child hood and Adolescence, First 
Edition, P-407-419. 
43. RUDOLPH’S Pediatrics, 21st Edition, P-1961to2281, 2315. 
44. SIDDHARTH N.SHAH, API Textbook of Medicine, seventh Edition,             
P-891-893. 
45. R.L.SOUHAMI, J.MOXHAM - Textbook of Medicine - Third Edition, P-1135. 
46. STEPHEN J.McPHEE, MAXINE, A.PAPADAKIS -2007 Current Medical 
Diagnosis and Treatment, Forty-Sixth Edition, P-1011, 1051, 1396. 
47. R.S.VASAN, SUDHA SESHADRI-Textbook of Medicine, P-421-423. 
48. WALTER G. BRADLEY, Neurology in Clinical   Practice, Fourth Edition, 
Volume II, P-2336-2345. 
49. The Washington Manual of Medical Therapeutics  GREEN, HARRIS, LIN, 
MOYLAN, Thirty Second Edition, P-693-695 
50. YADOLLAH HARATI - Neurologic Clinics - Peripheral Neuropathies –
February 2007, Volume 25, P- 32-33, 283. 
                                                   
PROFORMA 
 
Name                                  Age / sex   IP No. 
Place      Occupation  
 
History  
Duration of illness 
Progression of symptoms  
Motor symptoms 
Sensory symptoms 
Autonomic symptoms 
H/o respiratory distress  
Preceding respiratory or gastrointestinal illness 
H/o vaccination  
Any other relevant history  
 
Examination  
Higher mental functions 
 
Cranial nerves 
 
Spinomotor system  
Nutrition 
Tone 
Power  
Reflexes  
Neck muscle weakness 
Sensory system  
 
Autonomic system  
Orthostatic hypotension 
Sympathetic skin function   
Sudomotor  
Secretomotor 
               Pilomotor    
Gait  
Other systems  
RS 
           Chest expansion 
Single breath count 
Candle blow time 
Breath holding time  
CVS 
ABD 
Investigations  
Blood CBC  
Biochemistry 
  ECG 
Chest X-Ray PA view 
Pulmonary function tests 
CSF analysis  
 
Electrophysiological studies  
EMG  
CMAP 
Interference  
Recruitment  
Resting activity 
Insertional activity  
Nerve conduction studies  
Motor   
UL – median  
                       radial 
                       ulnar      
             LL -   posterior tibial 
                      Common peroneal  
      Sensory  
            UL -  median 
                     Ulnar  
            LL -  sural 
     Late responses  
           F wave  
           H reflex       
              
 RMS ADVANCE TESTING LAB 
181/5 PHASE I INDUSTRIAL AREA CHANDIAGARH 
PHONES 658701-705 
                                 Mr. Prakash                                                  35/M                                                        SNC RECORD 
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PHONES 658701-705 
                                 Mr. Krishnamoorthy                                                  64/M                                               SNC RECORD 
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                                 Mr. Shanmugam                                                  48/M                                               SNC RECORD 
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                                 Mrs. Maheswari                                                  35/F                                                      MNC RECORD 
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                                Mrs. Dhanabakkiyam                                                  46/F                                              MNC RECORD 
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                                 Mrs. Alamelu                                                            62/F                                            MNC RECORD 
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                                Mr. Munuswamy                                                  65/M                                               MNC RECORD 
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                                         Mr. Alexander                                                  25/M                                               MNC RECORD 
 
 
RMS ADVANCE TESTING LAB 
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CSF analysis 
S.No. Name Age /Sex IP.NO Clinical Presentation Antecedent events 
Co-existing 
Medical 
illness 
Autonomic 
dysfunction(including ECG) 
Serum 
potassium 
(meq/Lt) Protein 
mgs% Cell count 
MRI EMG Types Final outcome 
1 Govindaraj 33/M 838282 Weakness of UL, LL, neck muscles - - - 3.8 260 30 - AIDP Spontaneous recovery 
2 Maruthamuthu 78/M 838304 
Weakness of UL, LL, neck 
muscles, bulbar, respiratory 
muscles, sensory disturbance  
GE CAHD Ventricular arrythmias, Urinary retention 4.1 - - - AMAN Expired 
3 Alexander 25/M 838398 Weakness of UL, LL neck muscles - - - 4.0 1340 35 - AIDP 
Spontaneous and delayed 
recovery 
4 Renuka  23/F 838456 Weakness of UL, LL  - - Sinus Tachycardia 4.8 300 40 - AMAN  Spontaneous recovery 
5 Vadivelu 55/M 838821 Weakness of UL, LL  - - - 3.9 7280 20 - AIDP Spontaneous and delayed recovery 
6 Arunachalam 66/M 839907 
Weakness of UL, LL, neck , 
bulbar and respiratory muscles, 
sensory disturbance 
GE - Ventricular ectopics 3.9        - - - AIDP  Expired 
7 Shanmugam 48/M 841031 Weakness of UL, LL, neck muscles,     sensory disturbance URTI - Orthostatic hypotension 3.8 420 25 - AMSAN Spontaneous recovery 
8 Arul Victor 21/M 841099 Weakness of UL, LL - Hodgkin’s lymphoma - 4.2 1460 35 - AIDP 
Spontaneous and delayed 
recovery 
9 Maheswari 35/F 843233 Weakness of UL, LL, neck muscles - T2DM Orthostatic hypotension 4.4 570 30 - AMAN Spontaneous recovery 
10 Chidambaram 55/M 845312 Weakness of UL, LL, neck , bulbar and respiratory muscles - PT  Urinary retention 3.7 826 20 N AIDP 
Residual neurological 
deficit 
11 Jothi 45/F 847210 Weakness of UL, LL - - - 3.6 340 <10 - AMAN Spontaneous recovery 
12 Ramaraj 67/M 847817 Weakness of UL, LL, neck muscles,  sensory disturbance URTI - Ventricular ectopics 3.7 750 28 - AIDP 
Spontaneous and delayed 
recovery 
13 Rajeswari 32/F 848124 Weakness of UL, LL - - - 4.0 340 20 - AMAN  Spontaneous recovery 
14 Parimala 63/F 849378 
Weakness of UL, LL, neck, 
bulbar, ocular and respiratory 
muscles,     sensory disturbance 
GE T2DM Orthostatic hypotension  3.5 - - - AMSAN Discharged as AMA 
15 Kokilam  37/F 850014 Weakness of  LL - - - 4.3 600 <10 - AMAN Spontaneous and delayed recovery 
16 Elangovan 51/M 8541812 Weakness of  LL - - - 4.3 430 25 - AIDP  Spontaneous recovery 
17 Banumathi  22/F 853321 Weakness of UL, LL, neck, bulbar and  respiratory muscles     - - - 4.9 - - - AIDP  Spontaneous recovery  
CSF analysis 
S.No. Name Age /Sex IP.NO Clinical Presentation Antecedent events 
Co-existing 
Medical 
illness 
Autonomic 
dysfunction(including ECG) 
Serum 
potassium 
(meq/Lt) Protein 
mgs% Cell count 
MRI EMG Types Final outcome 
18 Dhanalakshmi 26/F 855114 Weakness of UL, LL, neck muscles      - - Sinus tachycardia, urinary retention 4.2 705 25 N AIDP 
Spontaneous and delayed 
recovery 
19 Renganathan  64/M 855999 sensory disturbance - - Urinary retention 5.0 800 28 - Sensory GBS 
Spontaneous and delayed 
recovery 
20 Vallarasan 16/M 856734 Weakness of UL, LL, neck muscles      - - - 4.7 430 15 - AIDP Spontaneous recovery 
21 Selvam  52/M 858458 
Weakness of UL, LL, neck, 
bulbar, and respiratory muscles,    
sensory disturbance 
URTI SHT/CAHD Ventricular arrhythmias 4.2 327 25 - AMSAN Spontaneous recovery 
22 Kalimuthu 50/M 858780 Weakness of  LL  - - - 4.6 945 <10 - AIDP Spontaneous and delayed recovery 
23 Muthuselvi 16/F 861325 Weakness of UL, LL,      - - - 4.5 600 36 - AMAN Spontaneous recovery 
24 Prakash 35/M 863210 Weakness of UL, LL, neck muscles,     sensory disturbance HIV - - 4.6 1120 250 - AMSAN Expired 
25 Manoj 30/M 864380 Weakness of UL, LL, neck, bulbar, and respiratory muscles,    URTI - - 5.0 810 22 - AIDP 
Spontaneous and delayed 
recovery 
26 Chitra  23/F 867370 Weakness of UL, LL,          neck muscles - - - 3.5 725 20 - AIDP  Spontaneous recovery 
27 Ganesan 43/M 868721 Weakness of UL, LL, neck, bulbar, and respiratory muscles - - - 3.7 - - - AIDP Discharged as AMA 
28 Dhanabakkiyam  46/F 869529 Weakness of UL, LL, neck muscles, sensory disturbance - - Orthostatic hypotension 3.7 608 26 - AMSAN Expired 
29 Sathish  18/M 869636 Weakness of UL, LL Vaccination for dog bite - - 4.1 300 <10 - AMAN Spontaneous recovery 
30 Alamelu 62/F 871027 
Weakness of UL, LL,          
neck  muscles,                 
sensory disturbance 
- - Orthostatic hypotension 4.0 810 36 - AMSAN Spontaneous and delayed recovery 
31 Ponnusamy 61/M 874109 
Weakness of UL, LL, neck, 
bulbar, and respiratory muscles,    
sensory disturbance 
GE PT Urinary retention 3.8 - - - AMSAM Discharged as AMA 
32 Alamelu  16/F 874145 Weakness of UL, LL - - Sinus Bradycardia  4.4 482 15 - AMAN Spontaneous recovery 
33 Nithish Kumar 20/M 877611 Weakness of UL, LL, neck, bulbar, and respiratory muscles,    - - - 5.0 - - - AIDP Spontaneous recovery 
CSF analysis 
S.No. Name Age /Sex IP.NO Clinical Presentation Antecedent events 
Co-existing 
Medical 
illness 
Autonomic 
dysfunction(including ECG) 
Serum 
potassium 
(meq/Lt) Protein 
mgs% Cell count 
MRI EMG Types Final outcome 
34 Balasubramaniyan 47/M 879271 Weakness of UL, LL       sensory disturbance - T2DM Orthostatic hypotension 4.9 705 15 - AMSAN Spontaneous recovery 
35 Rusiya 22/F 881321 Weakness of UL, LL,          neck muscles      - - Atrial ectopics 4.9 600 <10 - AIDP Spontaneous recovery 
36 Ashokan 45/M 881505 
Weakness of UL, LL, neck, 
bulbar, respiratory and ocular 
muscles, ataxia.     
URTI - - 4.5 327 26 - MFS Spontaneous recovery 
37 Arulmary 52/F 882773 Weakness of UL, LL        sensory disturbance - SHT Ventricular ectopics 3.5 945 30 - AIDP 
Spontaneous and delayed 
recovery 
38 Anand  28/M 888678 Weakness of UL, LL, neck  muscles  URTI - - 3.6 632 22 - AMAN Spontaneous recovery 
39 Munuswamy 65/M 899221 Weakness of UL, LL        sensory disturbance - - 
Orthostatic hypotension               
Urinary retention 3.5 430 25 N AIDP Spontaneous recovery 
40 Kumaran 25/M 907968 Weakness of UL, LL, neck, bulbar, and respiratory muscles     - - Urinary retention 4.8 1120 34 - AIDP 
Spontaneous and delayed 
recovery 
41 Krishnamoorthy 64/M 909916 Sensory Disturbance - - Sinus Tachycardia 4.7 850 25 - SENSORY GBS Spontaneous recovery 
42 Kavitha 27/F 912253 Weakness of UL, LL, neck, bulbar, and respiratory muscles     URTI - - 4.9 980 30 - AIDP 
Spontaneous and delayed 
recovery 
43 Rengaraj 45/M 917321 
Weakness of UL, LL, neck, 
bulbar, and respiratory muscles,    
sensory disturbance 
GE T2DM Ventricular ectopics 4.3 1442 45 N AIDP 
Residual neurological 
deficit 
44 Shanthi 35/F 923580 Weakness of UL, LL - - - 4.2 540 35 - AMSAN  Spontaneous recovery 
45 Karthikeyan 29/M 926360 Weakness of UL, LL,           neck muscles - - Orthostatic hypotension 3.6 756 30 - AIDP Spontaneous recovery 
46 Saroja 38/F 929302 Weakness of UL, LL, neck, bulbar, and respiratory muscles     - - - 3.9 - - - AIDP Expired 
47 Murugesan 58/M 931978 Weakness of  LL - - - 4.2 630 26 - AMAN Spontaneous recovery 
48 Neelavathy 28/F 936085 Weakness of  UL, LL  - - - 5.1 456 35 - AMAN Spontaneous recovery 
49 Pattu 55/F 941002 Weakness of  LL - - - 3.8 864 30 - AMAN Spontaneous and delayed recovery 
50 Rajendran 37/M 942019 Weakness of UL, LL,          neck muscles  - SHT - 3.6 1240 25 - AIDP 
Spontaneous and delayed 
recovery 
